Tirzepatide, a once-weekly dual agonist targeting both GLP-1 and GIP receptors, has demonstrated significant efficacy in managing both glycemic control and weight in individuals with type 2 diabetes (T2DM). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.